Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach

Synapse

Volumn 29, Issue 2, 1998, Pages 142-147

  Breier, Alan ^a,b   Adler, Caleb M ^a   Weisenfeld, Neil ^a   Su, Tung Ping ^a   Elman, Igor ^a   Picken, Lisa ^a   Malhotra, Anil K ^a   Pickar, David ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

11C raclopride; Dopamine; Glutamate; NMDA; Positron emission tomography; Schizophrenia

Indexed keywords

AMPHETAMINE; CARBON 11; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; KETAMINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RACLOPRIDE; SODIUM CHLORIDE;

ADULT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; AMPHETAMINE; BEHAVIOR; DOPAMINE; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; N-METHYLASPARTATE; NEOSTRIATUM; PSYCHIATRIC STATUS RATING SCALES; PSYCHOSES, SUBSTANCE-INDUCED; RACLOPRIDE; SALICYLAMIDES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031947285     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(199806)29:2<142::AID-SYN5>3.0.CO;2-7     Document Type: Article

References (58)

1. Bakker, C.B., and Amini F.B. (1961) Observations on the psychotomimetic effects of Sernyl. Compr. Psychiatry, 2:269-280.
2. Bakshi, V.P., Swerdlow, N.R., and Geyer, M.A. (1994) Clozapine antagonizes phenylcyclidine-induced deficits in sensorimotor gating of the startle response. J. Pharmacol. Exp. Ther., 271:787-794.
3. Ban, T.A., Lohrenz, J.J., and Lehmann, H.E. (1961) Observations on the action of Sernyl - a new psychotropic drug. Can. Psychiatr. Assoc. J., 6:150-156.
4. Breier, A., Buchanan, R.W., Kirkpatrick, B., Davis O.R., Irish, D., Summerfeit, A., and Carpenter, W.T. (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am. J. Psychiatry, 151(1):20-26.
5. Breier, A., Malhotra, A.K., Pinals, D.A., Weisenfeld, N., and Pickar, D. (1997a) Ketamine-induced psychosis is associated with focal activation of the prefrontal cortex in healthy volunteers. Am. J. Psychiatry, in press.
6. Breier, A., Su, T-P., Saunders, R.C., Carson, R.E., Kolachana, B.S., de Bartolomeis, A., Weinberger, D.R., Weisenfeld, N., Malhotra, A.K., Eckelman, W.C., and Pickar, D. (1997b) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci., USA 94:2564-2574.
7. Carlsson, M., and Carlsson, A. (1990) Schizophrenia: A subcortical neurotransmitter imbalance syndrome? Schizophrenia Bull., 16(3): 425-432.
8. Carson, R., Channing, M.A., Blasberg, R.G., Dunn, R.B., Cohen, R.M., Rice, K.C., and Herscovitch, P. (1993) An approximation formula for the variance of PET region-of-interest values. J. Cereb. Blood Flow Metab., 13:24-42.
9. 11C]-raclopride binding with continuous infusion. J. Cereb. Blood Flow Metab., in press.
10. Cheramy, A., Romo, R., Godeheu, G., Baruch, P., and Glowinski, J. (1986) In vivo presynaptic control of dopamine release in the cat caudate nucleus. II. Facilitatory or inhibitory influence of L-glutamate, Neuroscience, 19:1081-1090.
11. Cohen, M.L., Chan, S.L., Bhargava, H.N., and Trevor, A.J. (1974) Inhibition of mammalian brain acetylcholinesterase by ketamine. Biochem. Pharmacol., 23:1647-1652.
12. Corssen, G., and Domino, E.F. (1966) Dissociative anesthesia: Further pharmacologic studies and first clinical experience with the phencyclidine derivative CI-581. Anesth. Analg., 45:29-40.
13. Crosby, G., Crane, A.M., and Sokoloff, L. (1982) Local changes in cerebral glucose utilization during ketamine anesthesia. Anesthesiologist, 56:437-443.
14. Daly, D.A., and Maghaddam, B. (1993) Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci. Lett., 152:61-64.
15. Davis, B.M., and Beech, H.R. (1960) The effect of 1-arylcyclohexylamine (Sernyl) on twelve normal volunteers. J. Ment. Sci., 106:912-924.
16. Deutsch, S.I., Mastropaolo, J., Schwartz, B.L., Rosse, R.B., and Morihisa, J.M. (1989) Review: A "Glutamatergic Hypothesis" of schizophrenia rationale for pharmacotherapy with glycine. Clin. Neuropharmacolo., 12:1-13.
17. 11C-raclopride and positron emission tomography. J. Neurosci., 12(10):3773-3780.
18. Dewey, S.L., Smith, G.S., Logan, J., Brodie, J.D., Simkowitz, P., MacGregor, R.R., Fowler, J.S., Volkow, N.D., and Wolf, A.P. (1993a) Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc. Natl. Acad. Sci. USA, 90:11816-11820.
19. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse, 13:350-356.
20. Fischer, J., and Cho, A. (1979) Chemical release of dopamine from striatal homogenates: Evidence for an exchange diffusion model. J. Pharmacol. Exp. Ther., 192:642-653.
21. Fonnum, F., Storm-Mathisen, J., and Divac, I. (1981) Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibers in rat brain, Neuroscience, 6:863-873.
22. Gao, X.M., Shirakawa, O., Du, F., and Tamminga, C.A. (1993) Delayed regional metabolic actions of phencyclidine. Eur. J. Pharmacol., 241:7-15.
23. Giorguieff, M.F., Kermel, M.L., and Glowinski, J. (1977) Presynaptic effects of L-glutamic acid on the release of dopamine in rat striatal slices. Neurosci. Lett., 6:73-77.
24. Girault, J.A., Barbeito, L., Spampinato, U., Gozlan, H., Glowinski, J., and Besson, M.J. (1986) In vivo release of endogenous amino acids from the rat striatum: Further evidence for a role of glutamate and aspartate in corticostriatal neurotransmission. J. Neurochem., 47: 98-106.
25. Grace, A.A. (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: Schizophrenia. Neuroscience, 41(1):1-24.
26. Hammer, R.P., and Herkenham, M. (1983) Altered metabolic activity in the cerebral cortex of rats exposed to ketamine. J. Comp. Neurol., 220:396-404.
27. 123I] IBZM binding to the D2 receptor in nonhuman primates. Synapse, 10:177-184.
28. Ishimaru, M., Kurumaji, A., and Toru, M. (1992) NMDA-associated glycine binding site increases in schizophrenic brains. Biol. Psychiatry, 32:379-381.
29. Ishimaru, M., Kurumaji, A., and Toru, M. (1994): Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: Evidence for glutamate hypothesis. Biol. Psychiatry, 35:84-95.
30. Javitt, D.C., and Zukin, S.R. (1991) Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry, 148:1301-1308.
31. Kalivas, P.W., Duffy P., and Barrow, J. (1989) Regulation of the mesocorticolimbic dopamine system by glutamic acid receptor subtypes. J. Pharmacol. Exp. Ther., 251(1):378-389.
32. Kane, J., Honigfeld, G., Singer, J., and Meltzer, H. (1988) Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry, 45:789-796.
33. Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D., Heninger, G.R., Bowers, M.B., and Charney, D.S. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch. Gen. Psychiatry, 51:199-214.
34. Lahti, AC., Holcomb, H.H., Medoff, D.R., and Tamminga, C.A. (1995) Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport, 19:869-872.
35. Laruelle, M., Abi-Dargham, A., van Dyck, H., Gill, R., D'Souza, D., Erdos, J., McCance-Katz, E., Rosenblatt, W., Fingado, C., Zoghbi, S., Baldwin, R., Seibyl, J.P., Krystal, J., Charney, D., and Innis, R. (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. USA, 93:9235-9240.
36. Lidsky, T.I., Yablonsky-Alter, E., Zuck, L., and Banerjee, S.P. (1993) Anti-glutamatergic effects of clozapine. Neurosci. Lett., 163:155-158.
37. 11C]raclopride binding in the brain: Model simulations and kinetic analysis of PET data. J. Cereb. Blood Flow Metab., 14(6):995-1010.
38. Luby, E.D., Cohen, B.D., Rosenbaum, F., Gottlieb, J., and Kelley, R. (1959) Study of a new schizophrenomimetic drug, Sernyl. Arch. Neurol. Psychiatry, 81:363-369.
39. Malhotra, A.K., Pinals, D.A., Weingartner, H., Sirocco, K., Missar, C.D., Pickar, D., and Breier, A. (1996) NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology, 14:301-307.
40. Malhotra, A.K., Pinals, D.A., Adler, C.M., Elman, I., Clifton, A., Pickar, D., and Breier, A. (1997a) Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology, in press.
41. Malhotra, A.K., Adler, C.M., Kennison, S.D., Elman, I., Pickar, D., and Breier, A. (1997b) Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine. Biol. Psychiatry, in press.
42. Meibach, R.C., Glick, S.D., Cox, R., and Maayani, S. (1979) Localization of phencyclidine-induced changes in brain energy metabolism. Nature, 282:625-626.
43. Meyer, J.S., Greifenstein, F., and DeVault, M. (1959) A new drug causing symptoms of sensory deprivation. J. Nerv. Ment. Dis., 129:54-61.
44. Moghaddam, B. (1994) Recent basic findings in support of excitatory amino acid hypotheses of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 18:859-870.
45. Moghaddam, B., Gruen, R.J., Roth, R.H., Bunney, B.S., and Adams, R.N. (1990) Effect of L-glutamate on the release of striatal dopamine: In vivo dialysis and electrochemical studies. Brain Res., 518:55-60.
46. Moretti, R.J., Hassan, S.Z., Goodman, L.I., and Meltzer, H.Y. (1984): Comparison of ketamine and thiopental in healthy volunteers: Effects on mental status, mood, and personality. Anesth. Analg., 63:1087-1096.
47. Olney, J.W., and Farber, N.B. (1995) Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry, 52:998-1007.
48. Overall, J., and Gorham, D. (1962) The Brief Psychiatric Rating Scale. Psychol. Rep. 10:799-812.
49. Oye, I., Hustyveit, O., Moberg, E.R., Pausen, O., and Sloglund, L.A. (1991) The chiral forms of ketamine as probes for NMDA receptor function in humans. In: NMDA Receptor Related Agents: Biochemistry, Pharmacology, and Behavior. T. Kameyama, T. Nabeshima, and E.F. Domino, eds, NPP Books, Ann Arbor, MI, pp. 381-389.
50. Pandit, S.K., Kothary, S.P., and Kumar, S.M. (1980) Low dose intravenous infusion technique with ketamine. Anaesthesia, 35:669-675.
51. Sherman, A.D., Davidson, A.T., Baruah, S., Hegwood, T.S., and Waziri, R. (1991): Evidence of glutamatergic deficiency in schizophrenia. Neurosci. Lett., 121:77-80.
52. Smith, D.J., Pekoe, G.M., Martin, L.L., and Coalgate, B. (1980) The interaction of ketamine with the opiate receptor. Life Sci., 26:789-795.
53. Smith, D.J., Azzaro, A.J., Zaldivar, S.B., Palner, S., and Lee, H.S. (1981) Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. Neuropharmacology, 20:391-396.
54. Taber, M.T., and Fibiger, H.C. (1993) Electrical stimulation of the medial prefrontal cortex increases dopamine release in the striatum. Neuropsychopharmacology, 9(4):271-275.
55. Tamminga, C.A., Tanimoto, K., Kuo, S., Chase, T.N., Contreras, P.C., Rice, K.C., Jackson, A.E., and O'Donohue, T.L. (1987) PCP-induced alterations in cerebral glucose utilization in rat brain: Blockade by metaphit, a PCP-receptor-acylating agent. Synapse, 1:497-504.
56. Thomson, A., West, D., and Lodge, D. (1985) An N-methyl-D-aspartate receptor-mediated synapse in rat cerebral cortex: A site of action of ketamine? Nature, 313:479-481.
57. Tsai, G., Passani, L.A., Slusher, B.S., Carter, R., Baer, L., Kleinman, J.E., and Coyle, J.T. (1995) Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch. Gen. Psychiatry, 52:829-836.
58. Verma, A., and Moghaddam, B. (1996) NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: Modulation by dopamine. J. Neurosci., 16(1):373-379.